Browse studies

Find your next paid study

27,157 recruiting studies available now

Peripheral Neural Stimulation to Improve Microvascular Function and Limb Health in Veterans With Diabetic Peripheral Neuropathy

Establishing a sensitive, scalable physiological test for neurovascular reflex integrity and investigating whether targeted peripheral neural stimulation can e…

Lower Limb AmputeesDiabetes

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT07696988

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept wo…

Myelodysplastic Syndromes

A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Four-Way Crossover Study Evaluating the Abuse Potential of Two Doses of Gabapentin Taken Orally in Healthy, Non-Drug-Dependent Participants With Sedative Drug Use Experience

The purpose of the present study is to assess prospectively the abuse potential of gabapentin compared to placebo and alprazolam in healthy non-drug-dependent …

Healthy Non-dependent, Recreational Sedative Users

Estimated

~$10 – $8,750

Viatris Inc.NCT07777965

Phase 2

Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplima…

Head and Neck Squamous Cell Carcinoma (HNSCC)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT06769698

Phase 2

NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma

Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vo…

Neuroblastoma

Estimated

~$10 – $7,500

New Approaches to Neuroblastoma Therapy ConsortiumNCT07261241

Phase 1

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is saf…

Ovarian CancerLung AdenocarcinomaEndometrial Cancer+1 more

Estimated

~$10 – $7,500

AstraZenecaNCT05797168

Observational

Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality befor…

Cirrhosis, Liver

Estimated

~$10 – $6,250

The Cleveland ClinicNCT03208868

Observational

Investigation on the Cortical Communication (CortiCom) System

The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an ex…

TetraplegiaLocked-in SyndromeBrainstem Stroke+1 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT03567213

PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department: PERVADE-ED Study

Supraventricular tachycardia (SVT) is a dysrhythmia characterized rapid heart rate, typically with rapid onset. SVT accounts for over 50,000 emergency departme…

Supraventricular Tachycardia (SVT)

Estimated

~$10 – $750

University of IowaNCT07086560

Phase 2

A Pivotal Phase II Clinical Trial of Utidelone Injection (UTD1) Plus Capecitabine (CAP) in HER2-negative Breast Cancer Patients With Brain Metastases

This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-n…

HER2-negative Breast Cancer Patients With Brain Metastases

Estimated

~$10 – $8,750

Biostar Pharma, Inc.NCT06764940

Observational

Study to Evaluate the Clinical Utility of Radiation Exposure Reduction (SECURE): Multi-site Rampart Guardian Peripheral Trial

Radiation Protection

Estimated

~$10 – $7,500

Baylor Research InstituteNCT07467720

Observational

A Pediatric Emergency Department-based Intervention to Increase Infant Adherence to Safe Sleep Practices

Safe sleep recommendations from the American Academy of Pediatrics (AAP) are designed to reduce the risk of sudden infant death syndrome (SIDS) and other sleep…

Infant Safe Sleep PracticesSIDS

Estimated

~$10 – $6,250

State University of New York at BuffaloNCT07779512